AFT Pharmaceuticals Limited (ASX:AFP)

Market Cap	302.75M +18.5%
Revenue (ttm)	207.12M +19.0%
Net Income	15.30M +50.3%
EPS	0.14 +59.1%
Shares Out	n/a
PE Ratio	19.79
Forward PE	23.42
Dividend	0.02 (0.59%)
Ex-Dividend Date	Jun 18, 2025

Volume	837
Average Volume	2,012
Open	2.850
Previous Close	2.850
Day's Range	2.850 - 2.860
52-Week Range	2.200 - 3.370
Beta	0.38
RSI	38.68
Earnings Date	Feb 18, 2026

About AFT Pharmaceuticals

AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, pain management, skin care, vitamins, supplements, gastrointestinal, dermatology, and hospital. It has a research and development collaboration with Belgium’s Hyloris Pharmaceuticals to develop a novel innovative injecta...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 119
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AFP

Financial Performance

In fiscal year 2025, AFT Pharmaceuticals's revenue was 208.02 million, an increase of 6.45% compared to the previous year's 195.41 million. Earnings were 11.96 million, a decrease of -23.36%.

Financial numbers in NZD